Maternal and neonatal outcome after the use of g-csf for cancer treatment during pregnancy

Claudia Berends, Charlotte Maggen, Christianne A.R. Lok, Mathilde van Gerwen, Ingrid A. Boere, Vera E.R.A. Wolters, Kristel Van Calsteren, Heidi Segers, Marry M. van den Heuvel-Eibrink, Rebecca C. Painter, Mina Mhallem Gziri, Frédéric Amant*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)
2 Downloads (Pure)


Data on the use of Granulocyte colony-stimulating factor (G-CSF) in pregnant cancer patients are scarce. The International Network of Cancer, Infertility and Pregnancy (INCIP) reviewed data of pregnant patients treated with chemotherapy and G-CSF, and their offspring. Among 2083 registered patients, 42 pregnant patients received G-CSF for the following indications: recent chemotherapy induced febrile neutropenia (5; 12%), dose dense chemotherapy (28, 67%), poly chemotherapy (7, 17%), or prevention of neutropenia at delivery (2; 5%). Among 24 women receiving dose dense chemotherapy, three (13%) patients recovered from asymptomatic neutropenia within 5 days. One patient developed pancytopenia following polychemotherapy after which the pregnancy was complicated by chorioamnionitis and intrauterine death. Nineteen singleton livebirths (49%) were born preterm. Sixteen neonates (41%) were admitted to the Neonatal Intensive care Unit (NICU). No neonatal neutropenia occurred. Two neonates had congenital malformations. Out of 21 children in follow-up, there were four children with a motor development delay and two premature infants had a delay in cognitive development. In conclusion, the rate of maternal and neonatal complications are similar to those described in (pregnant) women treated with chemotherapy. Due to small numbers and limited follow-up, rare or delayed effects among offspring exposed to G-CSF in utero cannot be ruled out yet.

Original languageEnglish
Article number1214
Pages (from-to)1-12
Number of pages12
Issue number6
Publication statusPublished - 10 Mar 2021

Bibliographical note

Funding Information:
Funding: This project is funded by the European Union’s Horizon 2020 research and innovation program under grant agreement No 647047, “Kom Op Tegen Kanker” (Stand up to Cancer), the Flemish cancer society, “Stichting tegen Kanker”and Koningin Wilhelmina Fonds under project number 10094. Frédéric Amant is senior clinical investigator of the FWO.

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.


Dive into the research topics of 'Maternal and neonatal outcome after the use of g-csf for cancer treatment during pregnancy'. Together they form a unique fingerprint.

Cite this